Why Put The "N" in Nplate?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clinical reviewers had cold feet over Amgen's choice of Nplate as the trade name for its thrombopoeitin receptor agonist romiplostim, review documents show, but Amgen's argument that the brand name furthered its attempt to secure a global trademark carried the day
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class